According to the TCGA database, mutations in PPP6C (encoding phosphatase PP6) are found in approximately 10% of tumors from melanoma patients, where they coexist with BRAF and NRAS mutations. To assess PP6 function in melanoma carcinogenesis, we generated mice in which we could specifically induce BRAF (V600E) expression and delete Ppp6c in melanocytes. In these mice, melanoma susceptibility following UVB irradiation exhibited the following pattern: Ppp6c semi-deficient (heterozygous) > Ppp6c wild-type > Ppp6c-deficient (homozygous) tumor types. Next-generation sequencing of Ppp6c heterozygous and wild-type melanoma tumors revealed that all harbored Trp53 mutations. However, Ppp6c heterozygous tumors showed a higher signature 1 (mitotic/mitotic clock) mutation index than did Ppp6c wild-type tumors, suggesting increased cell division. Analysis of cell lines derived from either Ppp6c heterozygous or wild-type melanoma tissues showed that both formed tumors in nude mice, but Ppp6c heterozygous tumors grew faster than those from the wild-type line. Ppp6c knockdown via siRNA in the Ppp6c heterozygous line promoted accumulation of genomic damage and enhanced apoptosis relative to siRNA controls. We conclude that in the presence of BRAF (V600E) expression and UV-induced Trp53 mutation, Ppp6c haploinsufficiency promotes tumorigenesis.
This article is protected by copyright. All rights reserved.

Author